Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WC, Kirstein MN, Fouladi M, Seele LG, Wallace D, Houghton PJ, Gajjar A. Stewart CF, et al. Among authors: houghton pj. J Clin Oncol. 2004 Aug 15;22(16):3357-65. doi: 10.1200/JCO.2004.10.103. J Clin Oncol. 2004. PMID: 15310781 Clinical Trial.
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
Children's Oncology Group; Fouladi M, Furman WL, Chin T, Freeman BB 3rd, Dudkin L, Stewart CF, Krailo MD, Speights R, Ingle AM, Houghton PJ, Wright J, Adamson PC, Blaney SM. Children's Oncology Group, et al. Among authors: houghton pj. J Clin Oncol. 2006 Aug 1;24(22):3678-85. doi: 10.1200/JCO.2006.06.4964. J Clin Oncol. 2006. PMID: 16877737 Clinical Trial.
Phase I study of everolimus in pediatric patients with refractory solid tumors.
Fouladi M, Laningham F, Wu J, O'Shaughnessy MA, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL. Fouladi M, et al. Among authors: houghton pj. J Clin Oncol. 2007 Oct 20;25(30):4806-12. doi: 10.1200/JCO.2007.11.4017. J Clin Oncol. 2007. PMID: 17947729 Clinical Trial.
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KR, Wu J, Gajjar AJ, Houghton PJ, Santana VM, Stewart CF. Furman WL, et al. Among authors: houghton pj. J Clin Oncol. 2009 Sep 20;27(27):4599-604. doi: 10.1200/JCO.2008.19.6642. Epub 2009 Aug 17. J Clin Oncol. 2009. PMID: 19687340 Free PMC article. Clinical Trial.
Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.
McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville MB, Navid F, Santana VM, Houghton PJ, Furman WL, Rodriguez-Galindo C. McGregor LM, et al. Among authors: houghton pj. Pediatr Blood Cancer. 2012 Mar;58(3):372-9. doi: 10.1002/pbc.23075. Epub 2011 Apr 20. Pediatr Blood Cancer. 2012. PMID: 21509928 Free PMC article. Clinical Trial.
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.
Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VM. Furman WL, et al. Among authors: houghton pj. Invest New Drugs. 2012 Aug;30(4):1660-70. doi: 10.1007/s10637-011-9724-3. Epub 2011 Jul 28. Invest New Drugs. 2012. PMID: 21796439 Free PMC article. Clinical Trial.
Clinical trials using irinotecan.
Houghton PJ, Santana VM. Houghton PJ, et al. J Pediatr Hematol Oncol. 2002 Feb;24(2):84-5. doi: 10.1097/00043426-200202000-00002. J Pediatr Hematol Oncol. 2002. PMID: 11990709 No abstract available.
589 results